Introduction:
Medicago, a major Canadian biotech company announced plans to build $245 million vaccine production facility in Quebec City.
Features:
Medicago’s new complex will be built in Quebec City’s Espace d’innovation D’Estimauville (Estimauville innovation park) and completed by 2019. It will regroup Medicago’s head office, research and development activities, and commercial production plant.
Medicago’s new 44 000 m2 facility will be located on a 90 000 m2 site. It will have the capacity to deliver up to 40 to 50 million doses of quadrivalent seasonal flu vaccines. In addition, work towards developing new products will take place over the upcoming years.
The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago’s Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years.
Specifications:
| Company Name | Medicago |
| Location | Quebec, Canada |
| Type | New Production Facility |
| Estimated Cost | $245 million |
| Project Completion Year | 2019 |
